UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~July~~August 0904, 2021

Flexion Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-36287	26-1388364	~~001-36287~~	~~26-1388364~~
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)	~~(Commission File Number)~~	~~(IRS EmployerIdentification No.)~~
10 Mall RoadSuite 301
10 Mall Road, Suite 301
Burlington, Massachusetts		01803		~~01803~~
(Address of Principal Executive Offices)		(Zip Code)		~~(Zip Code)~~

Registrant’s Telephone Number, Including Area Code: 781 -305-7777

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		TradingSymbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		FLXN		~~Nasdaq~~The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.02 ~~Departure~~Results of ~~Directors~~Operations orand ~~Certain~~Financial ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Condition.

~~(d)~~ On ~~July~~August 94, 2021, ~~the Board of Directors (the “Board”) of~~ Flexion Therapeutics, Inc. ~~(the~~issued ~~“Company”) appointed Mr. Utpal Koppikar as~~ a ~~director~~press ofrelease ~~the~~announcing ~~Company.~~its ~~Mr. Koppikar~~financial ~~will~~results ~~serve~~for ~~as a Class II director with an initial term expiring at~~ the ~~Company’s~~quarter ~~2022~~ended ~~annual meeting of stockholders~~June 30, ~~or until his earlier death~~2021, ~~resignation,~~and ormade ~~removal.~~available ~~Mr. Koppikar~~on ~~was~~its ~~also~~corporate ~~appointed~~website ~~to serve as~~ a ~~member~~presentation ~~and~~of ~~Chair~~certain ofadditional ~~the~~operating ~~Audit~~results. ~~Committee~~Copies of the ~~Board,~~press ~~replacing~~release ~~Mr. Patrick~~and ~~Mahaffy,~~presentation ~~who~~are ~~was~~attached ~~serving~~hereto ~~in an interim role~~ as aExhibits 99.1 ~~member~~ and ~~Chair~~99.2, ~~of that Committee~~respectively.

~~Mr.~~The information in this Item ~~Koppikar~~2.02 ~~will~~and ~~receive~~Exhibits ~~compensation~~99.1 inand ~~accordance~~99.2 ~~with~~is ~~the~~being ~~Company’s~~furnished ~~Non-Employee~~and ~~Director~~shall ~~Compensation~~not ~~Policy~~be ~~previously~~deemed “filed” asfor ~~Exhibit~~the purposes of Section ~~10.6~~18 toof the ~~Company’s~~Securities ~~Annual~~Exchange ~~Report~~Act onof ~~Form 10-K~~1934, ~~filed~~as ~~with~~amended, or the ~~Securities~~Exchange ~~and~~Act, ~~Exchange~~or ~~Commission~~otherwise onsubject ~~March 12~~to the liabilities of that section, ~~2020.~~nor ~~The~~shall ~~Company~~they ~~also~~be ~~entered~~deemed incorporated by reference into aany ~~standard~~filing ~~form~~under the Exchange Act or the Securities Act of ~~indemnity~~1933, ~~agreement~~as ~~with~~amended, ~~Mr. Koppikar~~except ~~effective~~as ~~upon~~expressly ~~his~~set ~~appointment~~forth toby ~~the~~specific ~~Board~~reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number		Description
99.1		Press Release of Flexion Therapeutics, Inc. dated August 4, 2021
99.2		Presentation of Flexion Therapeutics, Inc. dated August 4, 2021
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Flexion Therapeutics, Inc.
Date:	~~July~~August 124, 2021	By:	/s/ Mark S. Levine
			Mark S. LevineGeneral Counsel & Corporate Secretary
			Mark S. LevineGeneral Counsel and Corporate Secretary

Filing Compare · Flexion Therapeutics Inc